- Canada’s Drug Agency (CDA-AMC) has issued a positive reimbursement recommendation for Bimzelx (bimekizumab) for adults with moderate-to-severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic therapy.
- The recommendation is supported by data from the Phase III BE HEARD I and BE HEARD II trials, alongside patient and clinician input highlighting the significant unmet need in HS.
- HS is a chronic inflammatory skin disease marked by painful nodules, abscesses, and draining lesions that can severely impact quality of life, mental health, and daily functioning.
- UCB Canada will now engage with public and private payers to expand access to Bimzelx, providing clinicians with an additional treatment option for patients with this often under-recognized and difficult-to-treat condition.
Takeaways:
The positive recommendation from CDA-AMC, backed by Phase III BE HEARD I and II trials, should accelerate payer negotiations and improve access for patients with chronic, painful nodules, abscesses, and draining lesions that impair quality of life and mental health. For the market, this establishes UCB Canada with a differentiated HS therapy, likely capturing a new high-value niche in dermatology biologics.
Source: CA Newswire
